Log In
Print
BCIQ
Print
Print this Print this
 

KU-046

  Manage Alerts
Collapse Summary General Information
Company Kareus Therapeutics S.A.
DescriptionCombination of a generally recognized as safe (GRAS) molecule combined with a marketed non-Alzheimer's disease product using Kareus' Karlect technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Quintiles Transnational Holdings Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today